Mark started his scientific career in 1999 with a diploma in Biology at the University of Bremen, Germany. In his diploma thesis he already worked in the field of Immuno-PCR, by implementing a competitor DNA in the methodology of IPCR-ELOSA.
After three years in a biotech company, Mark went to the University of Dortmund to earn his PhD in the emerging field of directed protein evolution. Mark joint Chimera Biotec in June 2008 where he became Director of Project Management in 2010 and CEO in 2014. Mark is author and co-author of several peer reviewed publications and presentations at scientific conferences and an active member of the American Association of Pharmaceutical Scientists (AAPS) emerging technologies committee.